TY - JOUR
T1 - Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
AU - Xu-Monette, Zijun Y.
AU - Dabaja, Bouthaina S.
AU - Wang, Xiaoxiao
AU - Tu, Meifeng
AU - Manyam, Ganiraju C.
AU - Tzankov, Alexander
AU - Xia, Yi
AU - Zhang, Li
AU - Sun, Ruifang
AU - Visco, Carlo
AU - Dybkaer, Karen
AU - Yin, Lihui
AU - Chiu, April
AU - Orazi, Attilio
AU - Zu, Youli
AU - Bhagat, Govind
AU - Richards, Kristy L.
AU - Hsi, Eric D.
AU - Choi, William W L
AU - Van Krieken, J. Han
AU - Huh, Jooryung
AU - Ponzoni, Maurilio
AU - Ferreri, Andrés J M
AU - Møller, Michael B.
AU - Parsons, Ben M.
AU - Zhao, Xiaoying
AU - Winter, Jane N.
AU - Piris, Miguel A.
AU - McDonnell, Timothy J.
AU - Miranda, Roberto N.
AU - Li, Yong
AU - Medeiros, L. Jeffrey
AU - Young, Ken H.
N1 - Funding Information:
This study was supported by the National Cancer Institute/National Institutes of Health (R01CA138688, R01CA187415 and 1RC1CA146299 to YL and KHY). ZYXM is the recipient of the Harold C and Mary L Daily Endowment Fellowships and Shannon Timmins Fellowship for Leukemia Research Award. GM is supported by a grant from the Michael and Susan Dell Foundation. KHY is supported by The University of Texas MD Anderson Cancer Center Lymphoma Moonshot Program, Institutional Research and Development Fund, an Institutional Research Grant Award, an MD Anderson Cancer Center Lymphoma Specialized Programs on Research Excellence (SPORE) Research Development Program Award, an MD Anderson Cancer Center Myeloma SPORE Research Development Program Award, a Gundersen Lutheran Medical Foundation Award, and partially supported by the National Cancer Institute/National Institutes of Health (P50CA136411 and P50CA142509), and by MD Anderson’s Cancer Center Support Grant CA016672.
Publisher Copyright:
© 2015 USCAP, Inc.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - MYC dysregulation, including MYC gene rearrangement and Myc protein overexpression, is of increasing clinical importance in diffuse large B-cell lymphoma (DLBCL). However, the roles of MYC and the relative importance of rearrangement vs overexpression remain to be refined. Gaining knowledge about the tumor biology associated with MYC dysregulation is important to understand the roles of MYC and MYC-associated biology in lymphomagenesis. In this study, we determined MYC rearrangement status (n=344) and Myc expression (n=535) in a well-characterized DLBCL cohort, individually assessed the clinical and pathobiological features of patients with MYC rearrangement and Myc protein overexpression, and analyzed the prognosis and gene expression profiling signatures associated with these MYC abnormalities in germinal center B-cell-like and activated B-cell-like DLBCL. Our results showed that the prognostic importance of MYC rearrangement vs Myc overexpression is significantly different in germinal center B-cell-like vs activated B-cell-like DLBCL. In germinal center B-cell-like DLBCL, MYC-rearranged germinal center B-cell-like DLBCL patients with Myc overexpression significantly contributed to the clinical, biological, and prognostic characteristics of the overall Myc-overexpressing germinal center B-cell-like DLBCL group. In contrast, in activated B-cell-like DLBCL, the occurrence, clinical and biological features, and prognosis of Myc overexpression were independent of MYC rearrangement. High Myc levels and Myc-independent mechanisms, either tumor cell intrinsic or related to tumor microenvironment, conferred significantly worse survival to MYC-rearranged germinal center B-cell-like DLBCL patients, even among Myc high Bcl-2 high DLBCL patients. This study provides new insight into the tumor biology and prognostic effects associated with MYC dysregulation and suggest that detection of both MYC translocations and evaluation of Myc and Bcl-2 expression is necessary to predict the prognosis of DLBCL patients.
AB - MYC dysregulation, including MYC gene rearrangement and Myc protein overexpression, is of increasing clinical importance in diffuse large B-cell lymphoma (DLBCL). However, the roles of MYC and the relative importance of rearrangement vs overexpression remain to be refined. Gaining knowledge about the tumor biology associated with MYC dysregulation is important to understand the roles of MYC and MYC-associated biology in lymphomagenesis. In this study, we determined MYC rearrangement status (n=344) and Myc expression (n=535) in a well-characterized DLBCL cohort, individually assessed the clinical and pathobiological features of patients with MYC rearrangement and Myc protein overexpression, and analyzed the prognosis and gene expression profiling signatures associated with these MYC abnormalities in germinal center B-cell-like and activated B-cell-like DLBCL. Our results showed that the prognostic importance of MYC rearrangement vs Myc overexpression is significantly different in germinal center B-cell-like vs activated B-cell-like DLBCL. In germinal center B-cell-like DLBCL, MYC-rearranged germinal center B-cell-like DLBCL patients with Myc overexpression significantly contributed to the clinical, biological, and prognostic characteristics of the overall Myc-overexpressing germinal center B-cell-like DLBCL group. In contrast, in activated B-cell-like DLBCL, the occurrence, clinical and biological features, and prognosis of Myc overexpression were independent of MYC rearrangement. High Myc levels and Myc-independent mechanisms, either tumor cell intrinsic or related to tumor microenvironment, conferred significantly worse survival to MYC-rearranged germinal center B-cell-like DLBCL patients, even among Myc high Bcl-2 high DLBCL patients. This study provides new insight into the tumor biology and prognostic effects associated with MYC dysregulation and suggest that detection of both MYC translocations and evaluation of Myc and Bcl-2 expression is necessary to predict the prognosis of DLBCL patients.
UR - http://www.scopus.com/inward/record.url?scp=84949535547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949535547&partnerID=8YFLogxK
U2 - 10.1038/modpathol.2015.118
DO - 10.1038/modpathol.2015.118
M3 - Article
C2 - 26541272
AN - SCOPUS:84949535547
SN - 0893-3952
VL - 28
SP - 1555
EP - 1573
JO - Modern Pathology
JF - Modern Pathology
IS - 12
ER -